WuXi AppTec's plan to build a factory in the US: Will it be sabotaged by political pressure?

Executive brief

Core judgment: Under the base case, the Delaware facility will maintain a dynamic balance of 'construction continues, litigation proceeds,' but the pace of legal remedies is unlikely to outstrip the time lag in customers' preventive compliance. Commercial trust erosion may occur before judicial rulings.

Stance landscape: The pro-facility and wait-and-see camps are roughly equal in strength. The former insists that delivery performance outweighs political statements; the latter worries that list labels erode private-sector compliance systems. Judicial and administrative agencies act as stabilizers maintaining the status quo.

Key risk: The mismatch between the irreversibility of high sunk costs and customers' risk-aversion instincts. Even if ultimately victorious in court, order loss and asset impairment may cause substantial damage before the judgment takes effect.

Turning-point signals: Monitor whether capacity utilization meets targets during the initial production phase at the Delaware facility, whether non-US multinational pharmaceutical companies have signed substantive backup agreements, and whether competitors' US expansion overlaps with restricted windows.

Recommended actions: Immediately launch transparent anchoring actions with core customers, replacing uncontrollable political maneuvering with verifiable local delivery performance to hedge against confidence erosion caused by preventive compliance.

This executive brief summarizes the report's conclusions. See corresponding chapters in the main text for the basis and sources of each judgment.

Key stakeholder stance distribution: Parallel tensions between commercial necessity and national security reviews

This section focuses on the divergence in attitudes toward the proposition that WuXi AppTec should build a factory in the US and develop contingency plans under Sino-US competition, as well as the underlying logic. Simulation statistics show that among 99 valid stance posts, supporters account for 51.5% (51 posts), viewing factory construction as a commercial necessity to be close to customers and ensure delivery; wait-and-see observers account for 32.3% (32 posts), concerned about the long-term spillover effects of national security reviews; neutral and procedural statements account for 16.2% (16 posts). The overall public opinion presents a tension structure of "parallel Game between commercial logic and political security," with supporters emphasizing sunk costs and real customer needs, while observers focus on the potential erosion of private sector compliance systems by list labels.

Support Camp: Mainly consisting of enterprises, local governments, and some customers, with the core logic being 'delivery performance outweighs political statements'. WuXi STA and WuXi AppTec executives repeatedly emphasized in the simulation that the Delaware base construction is a pragmatic arrangement driven by customer orders, not blind expansion. A character based on Chen Minzhang pointed out in the simulation that building overseas is a "must-answer question," and customer trust is accumulated through delivery rather than statements (Source: simulation). This stance was echoed by the Delaware State Government, which expressed welcome for investment and promised to advance compliance reviews according to laws and regulations, reflecting a separation between local economic interests and federal security concerns. Although global pharmaceutical clients hold a cautious attitude, they acknowledge that localized production capacity helps alleviate compliance and logistics anxieties. The visit of companies like BridgeBio to the open day on June 11, 2026, is seen as a signal of real industry demand (Source: material). Online verification confirms that WuXi STA announced the construction of an integrated base in Delaware in 2021, and this base is positioned as the eighth global R&D and production base (Source: verified online, sta.wuxiapptec.com).

Wait-and-See Camp: Mainly consisting of capital markets, industry analysts, and some legislators, with core concerns about the "compliance spillover effect of the Section 1260H List". Jefferies analysts and Founder Securities both point out that although the list currently only restricts direct contracts with the Department of Defense, the "military-related" label may trigger risk supplier reviews within multinational pharmaceutical companies, leading to a marginal decline in customer confidence during the 5-year transition period (Source: simulation). The capital market role further warns that without verifiable data isolation and compliance solutions, sunk costs cannot be converted into value anchors recognized by the market. Gary Peters, as the initiator of the "Biosecure Act," while respecting the enterprise's right to appeal, insists that premature characterization should not be made before completing transparent review within the legislative framework (Source: simulation). This wait-and-see stance does not deny the factory construction itself but questions whether relying solely on physical construction can truly hedge against institutional risks in the current geopolitical environment.

Neutral and Procedural Forces: Mainly consisting of US government agencies, courts, and Congress, emphasizing 'rules first, judicial independence'. The Pentagon and the US Government clearly distinguished the functional boundaries between national security reviews and commercial operation assessments in the simulation, reiterating that list identification is based on statutory procedures and does not prohibit cooperation with private enterprises (Source: simulation). The US District Court for the District of Columbia strictly adheres to judicial neutrality, refusing to confirm or refute entity claims outside of court, emphasizing that everything depends on evidence and legal application (Source: simulation). These roles constitute the "stabilizer" of the current situation, neither denying the enterprise's commercial rights nor relaxing the security bottom line, keeping the situation in a dynamic balance of "litigation ongoing + construction uninterrupted." Notably, the mention of "80 Chinese enterprise groups" in the materials lacks original source corroboration; the list actually identifies 188 companies without distinguishing between groups and subsidiaries (Source: verified online, Source: Holland & Knight law firm interpretation), which suggests that we need to maintain rigorous standards when assessing the scope of sanctions.

Key divergence points and key uncertainties: Litigation outcomes are not the only variable

Key Points of Divergence and Key Uncertainties: Litigation Outcomes Are Not the Only Variable

Regarding the proposition that "WuXi AppTec should build a factory in the US and develop contingency plans amid Sino-US competition," while parties have reached a basic consensus on commercial necessity, there are profound divergences regarding risk transmission mechanisms and the effectiveness of time windows. The current focal point of controversy has evolved from a simple question of "whether the listing designation was incorrect" to a timing game over whether "legal relief speed can outpace clients' instinctive compliance-driven risk avoidance," with multiple key variables still undecided.

Core Divergence: Independence of Legal Procedures vs. Transmission of Commercial Confidence. The Simulation character based on Stephen Vanberg emphasizes that the 1260H list review is a procedural act based on a supply chain security assessment framework, restricting only direct Department of Defense contracts; it should not be blurred by commercial narratives, and security reviews and base construction in Delaware can proceed "in parallel" (Source: simulation). However, the Global Pharmaceutical Clients character states bluntly that although short-term cooperation is unrestricted, fiduciary duties require the board to initiate a "Plan B" assessment. "The 5-year transition period is not a safety cushion, but a countdown." The verification cycle for clients switching suppliers may exceed the policy clarification cycle (Source: simulation). The Jefferies Analyst character further points out that even if policies clarify in 2027-2028, if clients begin assessments in 2026, the switching action itself is already underway. WuXi AppTec faces the challenge of "whether it can offset client time anxiety through delivery certainty during the dispute period" (Source: simulation). This divergence reveals the essence of the current dilemma: legal "innocence" does not equal commercial "no risk."

Rigorous Definition of Fact Checking and Data Standards. When assessing the scope of sanctions, note that the mention of "80 Chinese corporate groups" in the materials lacks original source corroboration; actually, 188 companies were identified on the list, but no distinction was made between group and subsidiary counts (Source: verified online, url: Holland & Knight law firm interpretation). Additionally, the precise data regarding the Delaware base's "60.66% progress" and "budget of 4.434 billion RMB" has not yet been traced to original sources in public channels (original source not verified); when cited in the main text, they serve only as qualitative references, not as precise audit bases. Similarly, the specific content of Deputy Secretary of Defense Vanberg's October 2025 letter to Congress has not been confirmed by primary correspondence (original source not verified); related judgments are more based on the Deduction (deduction) of character stances in the Simulation.

Key Uncertainty Variables Determining Future Trajectories. Apart from litigation outcomes, the following three variables are currently undetermined by anyone but will substantially decide the final effectiveness of WuXi AppTec's Delaware layout:

• Marginal Changes in Client Contract Terms: Whether existing clients start adding defensive clauses such as "geopolitical trigger clauses," "alternative supplier backups," or shortened contract terms when renewing or signing new contracts. This is a signal of confidence loss appearing earlier than litigation verdicts. What to Watch: Monitor whether the average renewal cycle for WuXi AppTec's US client contracts shows a shortening trend between late 2026 and early 2027, and whether additional compliance requirements are attached to new GLP-1 peptide business orders.
• Connection Strength of Detailed Rules for the "Biosecure Act": Will the rules for publishing the list of "Companies of Concern" scheduled for December 2026 form an automatic linkage mechanism with the 1260H list, thereby substantially expanding restrictions originally limited to direct DoD contracts to private sector health insurance payments or federally funded projects? What to Watch: Closely monitor joint guidelines or interpretive documents released by the U.S. Department of Health and Human Services (HHS) and the Department of Defense around the time of the December 2026 list announcement, particularly regarding whether the definition of "restricted entities" covers affiliates of 1260H list enterprises.
• Pace of Capacity Utilization Ramp-up After Delaware Base Commissioning: During the period of unresolved legal disputes, can the already built capacity receive sufficient commercial orders to validate the commercial logic that "localized capacity can hedge geopolitical risks." What to Watch: Track actual capacity utilization data for the first 6 months after the Delaware base becomes operational, and whether substantial signing actions occur where non-U.S. multinational pharmaceutical companies (e.g., European, Japanese clients) treat it as a backup node in their global supply chains.

These variables collectively constitute a "second battlefield" transcending judicial victory or defeat. As the Founder Securities character in the Simulation stated, geopolitical policy variables remain the most core uncertainty factor for CXO sector valuations, and marginal declines in client confidence often occur before legal rulings are implemented (Source: simulation). Decision-makers must recognize that even if the court ultimately rules to remove the entity from the list, if these three variables have undergone irreversible negative drift during this period, the strategic value of the Delaware base will still be significantly diminished.

Risk warning: The dual squeeze of sunk costs and erosion of customer confidence

Risk Warning: Dual Squeeze from Sunk Costs and Erosion of Client Confidence

If WuXi AppTec continues to advance the Delaware base construction under current conditions and maintains its existing response strategy, it will face substantial operational risks and market backlash. This risk does not stem from sanctions hitting a single dimension, but rather from the mismatch on the timeline between the irreversibility of high sunk costs and clients' instinctive compliance-driven risk avoidance. Even if legal victory is ultimately achieved at the judicial level, trust erosion in the commercial sector may cause irreversible order loss before the judgment is implemented.

The "Lock-in Effect" of Capital Investment and Asset Impairment Risks. As a key link in WuXi AppTec's global production capacity layout, the Delaware base has entered deep-water territory. Source materials indicate that the base's construction progress is over halfway complete with a huge budget scale (this precise progress and budget data have not been traced back to their original sources), meaning the company has formed massive sunk costs. In the simulation, a stakeholder modeled after Jefferies analysts pointed out that factory construction progress and capital expenditures are already over half; sunk costs and client commitments constitute support for continuing the project, but also create significant exit barriers (Source: simulation). If the December 2026 list of "Biotechnology Companies of Concern" under the Biosecure Act is officially published and includes WuXi AppTec, or if the Section 1260H litigation falls into a long stalemate, this base may face the dilemma of being "idle upon completion" or operating at low load. More severely, since the base relies heavily on US-based clients to absorb capacity, once geopolitical factors cause clients to shift supply chains, these highly specific CXO assets will face substantial impairment risks, and the vacancy cannot easily be filled by switching to other non-US orders.

Implicit Order Loss Caused by Clients' "Preventive Compliance." Although Section 1260H explicitly only restricts direct Department of Defense contracts and does not involve private enterprise cooperation (Source: material), commercial clients' decision-making logic is often more conservative than legal provisions. In the simulation, a stakeholder modeled after Founder Securities analyzed that the fiduciary duties of client boards require them to proactively initiate alternative plan assessments; this "preventive compliance" behavior will impact order margins before judicial results are released (Source: simulation). From industry conventions, CXO clients typically require a relatively long verification cycle from evaluating alternative suppliers to actually completing the switch. If clients initiate "Plan B" due to uncertainty in the second half of 2026, even if policies become clear in 2027, the switching action itself may already be underway. This erosion of confidence is hidden and lagging; initially manifesting as adjustments such as shortened contract renewal cycles and phased delivery of new orders, rather than direct termination declarations. By the time it reflects in declining financial report revenues, the optimal intervention window is often missed.

The "Time Lag" Trap of Legal Litigation and Administrative Determination. WuXi AppTec filed a lawsuit on June 11, 2026, claiming "erroneous determination" (Source: material), but the speed of judicial relief may not match the pace of eroding commercial confidence. In the simulation, a stakeholder modeled after Stephen VanBerg emphasized that procedural review is independent of commercial assessment, with no preset exit logic (Source: simulation). This means that even if the court accepts the case, the Pentagon's listing determination remains valid at the administrative level, and the subsequent issuance of detailed implementation rules for the Biosecure Act may add new compliance pressures. Legal "undecided status" is precisely commercial "high risk"; during the lengthy litigation period, competitors may exploit this window to accelerate market share grabs. Additionally, caution is needed regarding deviations in source materials stating that "80 Chinese enterprise groups" were listed; actual lists identified 188 companies without distinguishing between group and subsidiary counts (Source: verified online, url: Holland & Knight law firm interpretation). This information ambiguity itself exacerbates overseas clients' doubts about the overall security of China's supply chain, generating negative spillover effects beyond a single enterprise.

Limitations of Global Capacity Hedging Strategies. Although WuXi AppTec is advancing Singapore base construction (progress reaching 16.51%) to diversify risks (Source: material), given that the Delaware base is deeply bound to US client demands, Singapore capacity is unlikely to fully absorb orders potentially overflowing from the US in the short term. Particularly in fields like GLP-1 polypeptide business requiring extremely high supply chain response speeds, clients prefer localization or near-shoring. If the Delaware base loses its "localization" trust premium due to political labeling, its strategic value will distort from an "advantage close to clients" into a "target exposing risks," thereby dragging down the company's overall valuation system.

Recommended actions: Dynamic contingency plans based on three scenarios

Recommended actions: Dynamic contingency plans based on three scenarios

Regarding the proposition that "WuXi AppTec should build a factory in the US and formulate contingency plans under Sino-US competition," given the time-lag game between legal remedies and loss of customer confidence, a single strategy can no longer cover the current complex situation. It is recommended that the decision-making layer abandon the static mindset of "waiting for judgment" and establish a dynamic response mechanism with the publication of the December 2026 "Companies of Concern" list under the Biosecure Act as the key watershed. The following recommendations, based on the key uncertainties identified earlier, are broken down into executable plans for three scenarios.

1. Base Case: List label maintained but judicial proceedings unresolved, customers enter a "preventive compliance" wait-and-see period

This scenario assumes that by the first half of 2027, court litigation is still ongoing, the 1260H list has not been revoked, but the detailed rules of the upgraded Biosecure Act have not fully taken effect or provide certain exemption windows. This is the most probable path currently.

• "Transparency anchoring" action for core customers: Should not stop at verbal commitments; it is necessary to proactively disclose the production ramp-up curve and ROIC calculation model after the Delaware facility starts production to key customers such as BridgeBio and Neurocrine. In the simulation, a stakeholder modeled on Founder Securities pointed out that what the market lacks most is quantitative data rather than qualitative statements; only by proving that localized delivery can hedge cost premiums can the fiduciary anxiety of customer boards be alleviated (Source: simulation).
• "Expectation management" action for the capital markets: Clearly distinguish the rhythm differences between "Existing stock order transfer" and "incremental customer acquisition" during earnings calls. Acknowledge the reality of margin pressure during the ramp-up period, but use the commercial foundation of 58 billion yuan in backlog orders for GLP-1 peptide business to demonstrate long-term value (Source: material), avoiding excessive discounting by the market due to short-term financial fluctuations.
• Signals to watch: Focus on monitoring whether the renewal cycle of existing US customer contracts shows a trend of shortening, and whether new contracts include "geopolitical force majeure clauses" or "batch delivery" requirements. These marginal changes reflect true commercial temperature more than litigation progress.

2. Best Case: Substantive breakthroughs in judicial victory or legislative exemptions, brief trust window opens

This scenario assumes that the court rules to remove the list, or the "Companies of Concern" list published in December 2026 excludes CRDMO enterprises through detailed rules, causing geopolitical risk premiums to fall significantly.

• "Accelerated filling" action for capacity release: Utilize the golden window for trust repair to prioritize pushing European and Asia-Pacific multinational pharmaceutical companies to include the Delaware facility as a global supply chain backup node. In the simulation, a stakeholder modeled on the CEO of WuXi STA emphasized that Phase I should prioritize undertaking mature orders to lock in base utilization rates (Source: simulation); under the best case, further make "non-US clients" the key lever to verify the global attributes of the facility.
• "Third-party endorsement" action for the compliance system: Hire top international audit firms to conduct special certifications on data integrity and trade compliance at the Delaware facility, and embed the results into customer due diligence packages. Although WuXi AppTec's "Code of Business Conduct" has established feedback mechanisms and zero-tolerance principles (Source: verified online, url: officialsite-static.wuxiapptec.com), during politically sensitive periods, external independent verification is more persuasive than internal statements.
• Signals to watch: Pay attention to substantive signing actions by non-US multinational pharmaceutical companies, and public interpretation remarks by officials from the US Department of Defense or Commerce regarding the ruling/exemption. If official statements are ambiguous, even with a legal victory, recovery of commercial confidence will still lag.

3. Worst Case: List solidification and legislative restrictions upgrade, Delaware facility faces "asset island" risk

This scenario assumes that the December 2026 list explicitly covers WuXi AppTec, and transition period rules are strict, leading private sector customers to Large-scale launch Plan B, with the Delaware facility's capacity utilization rate remaining below the breakeven point for a long time.

• "Stop-loss and reconstruction" action for asset allocation: Immediately initiate an assessment of functional repositioning for the Delaware facility. If it cannot operate as CXO commercial capacity, explore feasibility for conversion into a pure R&D center, technology licensing platform, or joint venture operation with US partners, to avoid huge sunk costs continuously dragging down financial reports. In the simulation, a stakeholder modeled on a Jefferies analyst warned that sunk costs are both a reason to continue advancing and may become a valuation black hole (Source: simulation).
• "Stress test" action for the global network: Accelerate construction of the Singapore facility (current progress 16.51%) and evaluate its actual capacity ceiling to undertake overflow orders from the US. Note the information bias risks pointed out by material verification; conduct independent verification of the real carrying capacity of overseas capacity rather than relying on planning data.
• Signals to watch: Closely monitor whether there are cases where new customers for the GLP-1 peptide business refuse to sign due to compliance requirements, and expansion announcements by competitors (such as Lonza, Catalent) in the US Local. If competitor capacity launch times overlap with WuXi AppTec's restricted window, the urgency of asset reconstruction will rise exponentially.

The above three scenarios are not mutually exclusive; decision-makers need to establish a monthly review mechanism to dynamically adjust resource allocation based on the drift direction of observation indicators. Regardless of which scenario unfolds, replacing uncontrollable political games with verifiable delivery performance remains the only certainty for navigating cycles.

Materials and Sources

Verified Online Sources

• WuXi AppTec to Establish Formulation Production Base in Delaware, USA | WuXi STA
• Code of Business Conduct for WuXi AppTec Co., Ltd.

Material Sources

• guancha.cn
• cn.nytimes.com
• phirda.com